<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132814">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908478</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-ABT888-0002</org_study_id>
    <nct_id>NCT01908478</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer</brief_title>
  <acronym>VelGemRad</acronym>
  <official_title>A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I Study of veliparib (ABT-888) in combination with Gemcitabine and Intensity
      Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic
      Cancer.

      Primary Objectives:

        -  Determine the maximum tolerable dose of veliparib in combination with gemcitabine and
           intensity modulated radiation therapy in patients with locally advanced pancreatic
           cancer.

        -  Determine the safety and toxicity of the combination of veliparib with gemcitabine and
           radiation therapy in patients with locally advanced pancreatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine will be administered by intravenous infusion of 1000 mg/m2 over 30 minutes on
      days 1, 8, 15 of the cycle. Intensity modulated radiation therapy (IMRT) will be given to a
      total dose of 36 Gy in 15 fractions (2.4 Gy per fraction, one fraction per day, 5 fractions
      per week, Monday through Friday) beginning on day 1. Veliparib will be administered per a
      dose escalation schema.  The starting dose of veliparib is 20 mg BID based upon
      safety/efficacy data available.  Dose escalation will continue in 20 mg increments until the
      maximum tolerated dose (MTD) is reached.  Intra-patient dose escalation will not be allowed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)</measure>
    <time_frame>Days 1-70</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of objective response rates measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</measure>
    <time_frame>From baseline to Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pre-treatment biopsy specimens for levels of various DNA repair proteins</measure>
    <time_frame>Baseline only</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells</measure>
    <time_frame>Baseline, Weekly for 6 weeks, and at Weeks 10, 18, and 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Combination: veliparib, gemcitabine, and IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <arm_group_label>Combination: veliparib, gemcitabine, and IMRT</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Combination: veliparib, gemcitabine, and IMRT</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity modulated radiation therapy</intervention_name>
    <arm_group_label>Combination: veliparib, gemcitabine, and IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histopathological or cytological diagnosis of adenocarcinoma of the
             pancreas, as well as those with high clinical suspicion of adenocarcinoma, which is
             deemed unresectable

          -  Age 18 years or older

        Exclusion Criteria:

          -  Patients who have had prior anti-cancer treatment for their disease

          -  Patients who are currently receiving any other investigational agents

          -  Metastatic disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to PARP [Poly (ADP-ribosome) polymerase] inhibitors or gemcitabine

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Tuli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Chen</last_name>
    <phone>310-248-6773</phone>
    <email>Heather.Chen@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Swain-Cabrialles, RN</last_name>
    <phone>310-248-6733</phone>
    <email>Suzanne.SwainCabriales@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Chen</last_name>
      <phone>310-248-6773</phone>
      <email>Heather.Chen@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Swain Cabriales, RN</last_name>
      <phone>310-248-6733</phone>
      <email>Suzanne.SwainCabriales@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Wolin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard Sandler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Nissen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Colquhoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Miles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hoffman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youram Nassir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sepehr Rokhsar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Pandol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Wachsman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Richard Tuli, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>locally advanced</keyword>
  <keyword>unresectable</keyword>
  <keyword>pancreatic</keyword>
  <keyword>pancreas</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
